The authors suggested that combining sabatolimab and spartalizumab results in enhanced antitumor activity.61 This combination was studied in another phase II trial, NCT02608268, which included 16 patients with melanoma.62 In addition, a phase I/II trial NCT04370704 is studying the combination of antibodies against PD-1 (INCMGA00012), LAG-3 (INCAGN02385), and TIM-3 (INCAGN02390) in selected tumors, including melanoma.63 The gene discussed is LAG3; the disease is melanoma.